Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1995P - Clinical significance of cannabinoid receptor CB2 expression in non-small cell lung cancer (NSCLC)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Pathology/Molecular Biology

Tumour Site

Thoracic Malignancies

Presenters

Nikolaos Tsoukalas

Citation

Annals of Oncology (2020) 31 (suppl_4): S1052-S1064. 10.1016/annonc/annonc295

Authors

N.G. Tsoukalas1, C. Giaginis2, P. Alexandrou2, M. Liontos2, M. Tolia1, M. Kiakou1, I. Sfiniadakis2, N. Kavantzas2, E. Patsouris2, S. Theocharis2

Author affiliations

  • 1 Oncology Dept, 417 NIMTS Army Veterans Hospital, 115 21 - Kolonaki (Athens)/GR
  • 2 First Department Of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens/GR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1995P

Background

Cannabinoid receptor CB2 expression has been identified to be high in various malignant neoplasms and it is involved in the pathophysiological mechanisms related to carcinogenesis. Lung cancer is an important health problem and new biomarkers are needed for better patients’ stratification. This study was conducted to elucidate the clinical significance of cannabinoid receptor CB2 expression in NSCLC.

Methods

Cannabinoid receptor CB2 expression was evaluated immunohistochemically on Tissue MicroArrays (TMAs) of 79 tissue samples from NSCLC patients and it was correlated to clinicopathological parameters and overall survival (OS).

Results

79 NSCLC patients (48 adenocarcnomas and 31 squamous carcinomas) were studied. Enhanced cannabinoid receptor CB2 expression was observed in 20/79 (25.3%) NSCLC patients. In particular, enhanced cannabinoid receptor CB2 expression was found in 9 out of 48 (18.8%) adenocarcinomas and in 11 out of 31 (35.5%) of squamous cell carcinomas. Cannabinoid receptor CB2 expression was significantly associated with sex, smoking history and histological type (p=0.019, p=0.022 and p=0.032, respectively). In adenocarcinomas, cannabinoid receptor CB2 expression was correlated with overall survival (log-rank test, p=0.031), while there was a trend for correlation with tumor size (p=0.091) and lymph node metastasis (p=0.074). However, in squamous carcinomas cannabinoid receptor CB2 expression was not found to be significantly correlated with any of clinicopathological parameters or survival.

Conclusions

Cannabinoid receptor CB2 receptor may be involved in NSCLC malignant tranformation and growth particularly in adenocarcinomas. Therefore, cannabinoid receptor CB2 receptor could be considered as a potential biomarker or a therapeutic target in NSCLC. More studies needed to elucidate the role of this molecule in NSCLC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.